Literature DB >> 20430946

p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.

Björn K I Meijers1, Kathleen Claes, Bert Bammens, Henriette de Loor, Liesbeth Viaene, Kristin Verbeke, Dirk Kuypers, Yves Vanrenterghem, Pieter Evenepoel.   

Abstract

BACKGROUND AND OBJECTIVES: Cardiovascular disease is highly prevalent in chronic kidney disease. Traditional risk factors are insufficient to explain the high cardiovascular disease prevalence. Free p-cresol serum concentrations, mainly circulating as its derivative p-cresyl sulfate, are associated with cardiovascular disease in hemodialysis patients. It is not known if p-cresol is associated with cardiovascular disease in patients with chronic kidney disease not yet on dialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a prospective observational study in 499 patients with mild-to-moderate kidney disease, we examined the multivariate association between p-cresol free serum concentrations and cardiovascular events.
RESULTS: After a mean follow-up of 33 mo, 62 patients reached the primary end point of fatal or nonfatal cardiovascular events. Higher baseline concentrations of free p-cresol were directly associated with cardiovascular events (univariate hazard ratio [HR] 1.79, P<0.0001). In multivariate analysis, p-cresol remained a predictor of cardiovascular events, independent of GFR and independent of Framingham risk factors (full model, HR 1.39, P=0.04).
CONCLUSIONS: These findings suggest that p-cresol measurements may help to predict cardiovascular disease risk in renal patients over a wide range of residual renal function, beyond traditional markers of glomerular filtration. Whether p-cresol is a modifiable cardiovascular risk factor in CKD patients remains to be proven.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430946      PMCID: PMC2893077          DOI: 10.2215/CJN.07971109

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  25 in total

1.  Cardiovascular disease and chronic renal disease: a new paradigm.

Authors:  M J Sarnak; A S Levey
Journal:  Am J Kidney Dis       Date:  2000-04       Impact factor: 8.860

2.  Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.

Authors:  Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

Review 3.  Clinical epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

4.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

5.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

6.  Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.

Authors:  Fellype C Barreto; Daniela V Barreto; Sophie Liabeuf; Natalie Meert; Griet Glorieux; Mohammed Temmar; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 8.237

7.  The uremic retention solute p-cresyl sulfate and markers of endothelial damage.

Authors:  Björn K I Meijers; Soetkin Van Kerckhoven; Kristin Verbeke; Wim Dehaen; Yves Vanrenterghem; Marc F Hoylaerts; Pieter Evenepoel
Journal:  Am J Kidney Dis       Date:  2009-07-17       Impact factor: 8.860

8.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

9.  Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography.

Authors:  Henriette de Loor; Björn K I Meijers; Timothy W Meyer; Bert Bammens; Kristin Verbeke; Wim Dehaen; Pieter Evenepoel
Journal:  J Chromatogr A       Date:  2009-04-14       Impact factor: 4.759

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more
  115 in total

1.  Comparative Circadian Metabolomics Reveal Differential Effects of Nutritional Challenge in the Serum and Liver.

Authors:  Serena Abbondante; Kristin L Eckel-Mahan; Nicholas J Ceglia; Pierre Baldi; Paolo Sassone-Corsi
Journal:  J Biol Chem       Date:  2015-12-07       Impact factor: 5.157

2.  Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD.

Authors:  Ruben Poesen; Ali Ramezani; Kathleen Claes; Patrick Augustijns; Dirk Kuypers; Ian R Barrows; Jagadeesan Muralidharan; Pieter Evenepoel; Björn Meijers; Dominic S Raj
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-07       Impact factor: 8.237

3.  Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study.

Authors:  Rabi Yacoub; Girish N Nadkarni; Daniel I McSkimming; Lee D Chaves; Sham Abyad; Mark A Bryniarski; Amanda M Honan; Shruthi A Thomas; Madan Gowda; John C He; Jaime Uribarri
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-12

4.  Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.

Authors:  Liesbeth Viaene; Björn K I Meijers; Bert Bammens; Yves Vanrenterghem; Pieter Evenepoel
Journal:  Perit Dial Int       Date:  2013-10-31       Impact factor: 1.756

Review 5.  Uremic Toxins - Novel Arrhythmogenic Factor in Chronic Kidney Disease - Related Atrial Fibrillation.

Authors:  Shih-Yu Huang; Yi-Ann Chen; Shih-Ann Chen; Yi-Jen Chen; Yung-Kuo Lin
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

6.  Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.

Authors:  Tariq Shafi; Tammy L Sirich; Timothy W Meyer; Thomas H Hostetter; Natalie S Plummer; Seungyoung Hwang; Michal L Melamed; Tanushree Banerjee; Josef Coresh; Neil R Powe
Journal:  Kidney Int       Date:  2017-07-21       Impact factor: 10.612

7.  Diurnal and Long-term Variation in Plasma Concentrations and Renal Clearances of Circulating Markers of Kidney Proximal Tubular Secretion.

Authors:  Matthew B Rivara; Leila R Zelnick; Andrew N Hoofnagle; Rick Newitt; Russell P Tracy; Mario Kratz; David S Weigle; Bryan R Kestenbaum
Journal:  Clin Chem       Date:  2017-02-10       Impact factor: 8.327

8.  Can oral therapy reduce uremic toxins?

Authors:  Thomas A Depner; Larry D Cowgill
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 8.237

Review 9.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Authors:  Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

Review 10.  Prognostic significance and therapeutic option of heart rate variability in chronic kidney disease.

Authors:  Jing Zhang; Ningning Wang
Journal:  Int Urol Nephrol       Date:  2013-03-29       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.